Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific hails award-winning scientist

Vortex Biosciences' Elodie Sollier-Christen received the 2017 Society award for Laboratory Automation and Screening Innovation.
NetScientific hails award-winning scientist
Warm round of applause for Vortex Biosciences' Elodie Sollier-Christen

NetScientific PLC (LON:NSCI), the healthcare investment group, said the chief scientific officer of one of its investee companies has won industry recognition.

Vortex Biosciences' Elodie Sollier-Christen received the 2017 Society award for Laboratory Automation and Screening Innovation.

Her presentation to the judges was entitled Vortex Technology for fast and label-free isolation of circulating tumour cells from blood samples.

In it she discussed a breakthrough by Vortex in the isolation of circulating tumour cells from blood samples.

NetScientific chief executive François Martelet said: "We wish to extend our warm congratulations to Elodie on her receipt of this prestigious award.

“We view this prize as a recognition of her extraordinary work on the cutting edge technology utilised by  Vortex on the design of the VTX-1 liquid biopsy system.

“We believe that this technology has great potential to significantly impact laboratory automation and screening and we are delighted to see it receive due recognition."

Ian_55ae0ddd437b7.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.
cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use